The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
|Articles|April 25, 2023
World Immunization Week: The Latest Infectious Disease Vaccine Updates
Author(s)Nina Cosdon
The last week in April is World Immunization Week, and we're recapping the most recent and significant developments in infectious disease vaccines.
Advertisement
Celebrated in the last week of April, World Immunization Week highlights the importance of
"The ultimate goal of World Immunization Week is for more people—and their communities—to be protected from vaccine-preventable diseases," the World Health Organization
For 2023, the theme of World Immunization Week is The Big Catch-Up, emphasizing the urgency of ensuring children and other individuals who missed routine vaccinations during the COVID-19 pandemic are adequaltely protected against illness, disability, and death.
Contagion rounded up our top 5 stories on recent vaccine developments to raise awareness for World Immunization Week, encompassing the progress and setbacks in infectious disease vaccinations.
Advertisement
Related to this article
The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.
FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Here is a comprehensive list of vaccines approved this year as well as background information on the clinical data for each of them.
The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.
Advertisement
Advertisement